urothelial carcinoma (advanced) clinical trials results

atezolizumab versus chemotherapy
IMvigor211 (IC2/3), NCT02302807	atezolizumab versus chemotherapy	patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen	open label global
atezolizumab versus control
IMVIGOR-130 (monotherapy), 0 NCT02807636	Atezolizumab+Gemcitabine+Carboplatin/Cisplatin versus Placebo+Gemcitabine+Carboplatin/Cisplatin	Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma	open-design
atezolizumab versus nil
IMvigor210, NCT02951767	Atezolizumab versus single arm study	Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen
durvalumab versus nil
durvalumab phase 1/2,	durvalumab at 10 mg/kg body weight administered as an intravenous infusion over 60 minutes every two weeks until disease progression or unacceptable toxicity versus	patients with locally-advanced or metastatic urothelial carcinoma of the bladder who had progressed while on or after a platinum-containing chemotherapy, including those who progressed within 12 months of receiving therapy in a neoadjuvant or adjuvant setting
nivolumab versus nil
Checkmate 275, NCT02387996	nivolumab 3 mg/kg intravenously every 2 weeks until disease progression and clinical deterioration, unacceptable toxicity, or other protocol-defined reasons versus	patients with metastatic urothelial carcinoma after platinum therapy
pembrolizumab versus chemotherapy
KEYNOTE-045, 2017 NCT02256436	pembrolizumab versus investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine	patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy	open-label
Keynote 361 monotherapy, NCT02853305	pembrolizumab 200 mg every 3 weeks (Q3W) versus chemotherapy alone	patients with histologically or cytologically confirmed unresectable/metastatic urothelial carcinoma